Anthony Fauci, as director of the National Institute of Allergy and Infectious Diseases from 1984 onward, became the federal government’s most visible scientist during the AIDS epidemic and played a central role in shaping how AZT was tested, approved, and eventually folded into combination therapy. His involvement was never simple or universally praised. Fauci championed the rapid clinical testing of AZT at a time when no treatment existed, but he also became the target of fierce activist anger over the pace of drug trials, their restrictive eligibility criteria, and the government’s broader response to the crisis. Understanding what actually happened with AZT during those years requires separating the drug’s real clinical story from the political battles that surrounded it.
What AZT Was and Why It Mattered
Zidovudine, known widely as AZT, was originally synthesized in the 1960s as a potential cancer drug and shelved when it proved ineffective for that purpose. In 1985, researchers at the National Cancer Institute and Burroughs Wellcome found that it blocked HIV replication in the lab. The drug works by mimicking one of the building blocks that HIV’s reverse transcriptase enzyme needs to copy viral RNA into DNA. When the enzyme incorporates AZT instead of the real building block, the growing DNA chain is terminated because AZT lacks the chemical group needed to attach the next link.1Antimicrobial Agents and Chemotherapy. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase This chain-termination mechanism was simple and effective enough in lab dishes to warrant a fast move into human trials.
Fauci’s NIAID was instrumental in coordinating and funding the clinical infrastructure needed to test AZT in people. By the mid-1980s, the epidemic was killing thousands of young men, and there was no approved antiviral treatment of any kind for HIV. The political and medical pressure to find something that worked was immense, and Fauci publicly pushed for an accelerated testing timeline. That urgency would prove both justified and controversial.
The Pivotal 1986 Trial
The study that changed everything was a randomized, double-blind, placebo-controlled trial involving 282 patients with AIDS or advanced AIDS-related complex. Patients received either 250 mg of AZT or a placebo every four hours around the clock. The trial was stopped early because the results were so striking: 19 patients on placebo died during the study period, compared to just one patient receiving AZT. AZT also reduced the frequency of opportunistic infections during the eight to twenty-four weeks of observation.2New England Journal of Medicine. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
The lopsided mortality result made AZT the first drug ever approved by the FDA for treating HIV, and the approval came in March 1987, just twenty months after the drug entered human testing. That speed was unprecedented for a new antiviral and set the template for accelerated approval pathways that the FDA would later formalize. Fauci was publicly supportive of this rapid path, arguing that a fatal disease with no treatment warranted faster regulatory action than usual. Critics would later question whether the speed came at the cost of fully understanding the drug’s long-term risks.
The Toxicity Problem
AZT’s early promise came with a serious catch. The original dosing regimen, 1,200 mg per day, was brutal on patients’ bone marrow. The companion toxicity paper to the efficacy trial documented that about a quarter of AZT recipients developed severe anemia, with hemoglobin dropping below 7.5 grams per deciliter, compared to just 4 percent of those on placebo. Roughly one in five AZT patients needed multiple blood transfusions. Dangerous drops in white blood cell counts occurred in 16 percent of the AZT group versus 2 percent on placebo.3New England Journal of Medicine. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial Patients also reported nausea, muscle pain, insomnia, and severe headaches at much higher rates than those taking placebo.
These side effects were not minor inconveniences. For patients already weakened by AIDS, severe anemia and immune suppression from the very drug supposed to help them created a cruel paradox. Over time, clinicians learned that lower doses of AZT could preserve much of the antiviral benefit with far less toxicity, and doses were eventually cut substantially from the original regimen. But in those early years, many patients experienced the drug at its most punishing. AZT-induced anemia has remained a concern even in later use, particularly in resource-limited settings where the drug continued to be prescribed widely. A study in southern India found that roughly 15 percent of patients on AZT-containing regimens developed anemia, with those who already had low immune cell counts being hit hardest.4Europe PMC. High Incidence of Zidovudine Induced Anaemia in HIV Infected Patients in Southern Odisha
Activist Fury and the Fight Over Clinical Trials
The collision between Fauci and AIDS activists, particularly the group ACT UP, became one of the defining stories of American public health in the twentieth century. Activists were furious about several things at once: the price of AZT (Burroughs Wellcome set it at roughly $8,000 a year per patient, making it one of the most expensive drugs in history at the time), the slow pace of testing for other potential treatments, and the rigid structure of federal clinical trials that excluded many of the sickest patients as well as women, children, and injection drug users.
Fauci’s NIAID controlled the AIDS Clinical Trials Group, the main federally funded network running drug studies. Activists argued that the traditional placebo-controlled trial design was unethical when patients were dying and no alternatives existed. They demanded expanded access programs, parallel track systems that would let patients outside of trials receive experimental drugs, and a voice in how trials were designed. Fauci initially resisted some of these demands, but he shifted more than most government officials were willing to. He met repeatedly with activist leaders, eventually agreeing to broaden trial eligibility, establish parallel track access, and incorporate community input into trial design.
One concrete result was the creation of community advisory boards within federally funded AIDS research programs. Starting in 1989, community-based AIDS research programs received federal funding, and the Terry Beirn Community Programs for Clinical Research on AIDS required each research unit to maintain a community advisory board that could communicate community preferences and provide advice on study design.5Oxford Academic. Community advisory boards: their role in AIDS clinical trials This was a genuine structural change in how clinical research was conducted, and it grew directly out of the confrontation between activists and Fauci’s institute. Whether Fauci deserves credit for eventually listening or blame for not listening sooner depends on who you ask, and both perspectives have merit.
Buyers Clubs and the Underground Treatment Economy
While Fauci and federal agencies debated trial design, desperate patients were not waiting. Buyers clubs sprang up across the United States during the late 1980s, operating as informal networks that sourced and distributed treatments that were either unapproved in the U.S. or too expensive to obtain through conventional channels. These organizations focused on curating knowledge about potential treatments and getting drugs to patients who felt abandoned by the official system.6Taylor & Francis Online. Mapping buyer’s clubs; what role do they play in achieving equitable access to medicines?
The existence of buyers clubs was, in part, an indictment of how slowly the federal apparatus moved. Some patients turned to these networks because they could not get into NIAID-sponsored trials, which had strict enrollment criteria. Others simply could not afford AZT at its commercial price. The clubs distributed a range of substances, from drugs approved in other countries to compounds with little evidence behind them. Fauci’s public response to this underground economy evolved over time. Early on, he emphasized the importance of rigorous testing and warned against unproven therapies. Later, as he acknowledged the legitimacy of activist grievances, his tone softened, and the parallel track policy he helped implement was partly an attempt to offer a legal, monitored alternative to the black market.
The Concorde Trial and the Limits of Monotherapy
One of the most consequential challenges to AZT’s perceived value came from the Concorde trial, a large Anglo-French study that compared giving AZT immediately to asymptomatic HIV-positive people versus deferring it until symptoms appeared. The results were sobering. While markers associated with disease progression, such as CD4 counts, did show improvement in the group receiving AZT immediately, those improvements did not translate into better clinical outcomes. Markers associated with drug toxicity, like hemoglobin and white cell counts, favored the group that deferred treatment. In other words, AZT moved the lab numbers in the right direction but did not actually help asymptomatic patients live longer or stay healthier.7Oxford Academic. Markers of HIV infection in the Concorde trial
The Concorde findings arrived alongside a separate American study that raised related concerns about surrogate markers. Researchers found that while CD4 cell counts were correlated with progression to AIDS, only a small fraction of AZT’s clinical effect could be statistically explained by changes in those counts. A substantial portion of whatever benefit AZT provided appeared to operate through mechanisms that CD4 levels did not capture, particularly within the first sixteen weeks of therapy.8PubMed Central / Annals of Internal Medicine. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine
Together, these results meant two things. First, treating asymptomatic people with AZT alone was not worthwhile, and the push to prescribe it as early as possible had been premature. Second, the scientific community’s reliance on CD4 counts as a stand-in for clinical benefit was shakier than assumed. Fauci and other federal scientists had to reckon publicly with the fact that the early optimism around AZT monotherapy had been excessive. For activists and patients who had been taking high-dose AZT for years based on that optimism, the Concorde results felt like a betrayal. The drug that was supposed to save their lives was not delivering the long-term benefit they had been promised.
A Genuine Triumph in Preventing Mother-to-Child Transmission
If the Concorde trial represented the low point for AZT’s reputation, the ACTG 076 trial represented its redemption in a different population. Published in 1994, this study tested whether giving AZT to pregnant women with HIV and to their newborns could reduce the rate of mother-to-child transmission. The results were dramatic: the estimated infection rate at eighteen months was about 8 percent in the AZT group versus roughly 26 percent in the placebo group, a relative reduction in transmission risk of nearly 68 percent.9Massachusetts Medical Society / New England Journal of Medicine. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
This was one of the clearest, most unambiguous wins in the history of AIDS treatment. Fauci’s NIAID had funded the trial through its AIDS Clinical Trials Group, and the result transformed clinical practice almost immediately. The finding that a relatively simple drug regimen could prevent most cases of mother-to-child HIV transmission became the foundation for prevention-of-transmission programs worldwide. In wealthy countries, perinatal HIV transmission dropped to near zero as the protocol was adopted. In the developing world, simplified versions of the AZT regimen became a cornerstone of efforts to prevent pediatric AIDS, even as newer drugs eventually replaced AZT in many first-line regimens.
The Move to Combination Therapy
By the mid-1990s, the scientific consensus was shifting decisively away from AZT monotherapy. The core problem was resistance. HIV mutates rapidly, and when exposed to a single drug, the virus reliably evolves strains that can evade it. Research showed that AZT-resistant viruses developed at similar rates whether patients were on AZT alone or on AZT combined with another nucleoside drug like ddI or ddC. However, the combination arms showed lower rates of resistance to the second drug, which partly explained why two-drug regimens performed better clinically than monotherapy.10PubMed Central. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy
The real breakthrough came with the addition of protease inhibitors, a new class of drugs, to create three-drug regimens. A landmark trial published in 1997 compared three-drug therapy (indinavir plus AZT plus lamivudine) against two-drug or single-drug regimens. The results left little room for debate: after twenty-four weeks, roughly 90 percent of patients on the three-drug regimen had their viral load suppressed below detection limits, compared to about 43 percent on indinavir alone and zero percent on the AZT-lamivudine combination.11National Institutes of Health. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy This was the dawn of what became known as highly active antiretroviral therapy, or HAART, and it turned HIV from a death sentence into a manageable chronic condition for patients who could access it.
Fauci was an early and vocal advocate for combination therapy as the evidence accumulated. His institute funded much of the clinical trial infrastructure that produced these results, and he used his public platform to push for rapid adoption of three-drug regimens. In retrospect, the transition from AZT monotherapy to combination therapy is one of the clearest examples of biomedical science working as it is supposed to: an initial treatment is tried, its limitations are identified through rigorous trials, and it is replaced by something better. The process was messier and slower than it looks in hindsight, and real people suffered and died during the years it took to get there, but the scientific trajectory was ultimately sound.
How Fauci’s Role Is Remembered and Misremembered
Public memory of Fauci’s involvement with AZT has fractured into competing narratives that each capture part of the truth while distorting the rest. One narrative, popular among some conservatives and AIDS denialists, portrays Fauci as having pushed a toxic, useless drug on vulnerable patients for the benefit of pharmaceutical companies. Another, more common in mainstream accounts, casts him as a bureaucrat who eventually became an ally of activists and helped bring life-saving treatments to market. Neither version is fully accurate.
The toxic-drug narrative gets several things wrong. AZT was genuinely effective at reducing short-term mortality in patients with advanced AIDS, as the 1986 trial clearly showed. The drug’s toxicity was real and serious, but it was documented in parallel with its efficacy, and doses were reduced over time as clinicians learned more. The claim that AZT killed more people than it saved is not supported by the clinical trial data. What is true is that the early enthusiasm for AZT monotherapy outran the evidence, particularly regarding its use in asymptomatic patients, and that the high initial doses caused severe suffering that might have been avoided with more cautious prescribing.
The heroic-ally narrative also oversimplifies. Fauci was slow to respond to the crisis in its earliest years, as were virtually all federal officials. His initial resistance to activist demands for broader trial access and faster drug testing was real, and people died while those debates played out. When he did engage with activists, it was partly because their pressure made inaction politically untenable. His willingness to change course was genuine and consequential, but it came after years of activist sacrifice and confrontation that should not be folded into Fauci’s own story as though he initiated the changes on his own.
AZT’s Ongoing Use in the Developing World
While wealthier countries moved on to newer drug regimens years ago, AZT remained part of first-line treatment protocols in many low- and middle-income countries well into the 2000s and beyond. The drug is cheap to produce, off patent, and effective enough as part of a combination to remain a reasonable option where newer alternatives are unavailable or unaffordable. This continued use means that the toxicity profile documented in the 1980s remains clinically relevant today. Anemia continues to be a significant problem for patients on AZT-containing regimens, particularly those who start treatment with already-compromised immune systems.4Europe PMC. High Incidence of Zidovudine Induced Anaemia in HIV Infected Patients in Southern Odisha
The global health dimension of AZT’s story adds another layer to the debate about Fauci’s legacy. The prevention-of-mother-to-child-transmission protocols that grew out of NIAID-funded research have saved an enormous number of lives in sub-Saharan Africa and South Asia. At the same time, the years of delay before generic AZT became widely available in the developing world, and the U.S. government’s complicated relationship with pharmaceutical patent protections, meant that many of the people who needed AZT most went without it for the longest. Fauci’s institute produced the science that proved the drug worked; the political and economic systems that determined who could actually get it were largely beyond his direct control, though his public advocacy on access questions grew more pointed over the years.
The Resistance Mechanism and Why Monotherapy Was Doomed
Understanding why AZT alone was never going to be enough requires a brief look at how HIV fights back. When the virus’s reverse transcriptase enzyme encounters AZT blocking the end of a growing DNA chain, resistant strains of the virus develop an ability to use the cell’s own ATP molecules to remove the AZT roadblock and continue copying. Specific mutations in the reverse transcriptase gene enable this excision reaction, effectively allowing the virus to edit out the drug and keep replicating.1Antimicrobial Agents and Chemotherapy. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase This is not a slow process. HIV’s error-prone replication means resistant variants emerge quickly in any large viral population exposed to a single drug.
This biological reality is why the move to three-drug therapy was so transformative. Hitting the virus with drugs that target different steps of its life cycle makes it astronomically harder for any single viral particle to accumulate all the mutations needed to resist everything at once. The science behind this principle was emerging throughout the late 1980s and early 1990s, but translating it into proven clinical regimens took time and enormous trial infrastructure. Fauci’s NIAID provided much of that infrastructure, funding the trials that demonstrated two-drug combinations were better than monotherapy and that three-drug regimens were better still. The frustrating truth of the AZT era is that the biological limitations of monotherapy were becoming apparent even as the drug was being hailed as a miracle, and the institutional machinery needed to test better approaches could not move as fast as the epidemic demanded.